Carrie Geisberg Lenneman M.D., MSCI


M.D., Medical University of South Carolina, 2003
Residency, Internal Medicine, Vanderbilt University, 2006
Masters of Science and Clinical Investigation, Vanderbilt University, 2010
Fellowship, Cardiovascular Medicine, 2011
Board Certified, ABIM, Internal Medicine, 2006
Board Certified, ABIM Cardiovascular Medicine, 2011

Curriculum Vitae

Current Positions:

Assistant Professor of Medicine, Department of Medicine University of Louisville
Associate Program Director, Cardiovascular Fellowship Program
Director, Cardiovascular Research
Director, Cardio-Oncology Clinic

Clinical Focus and Research:

My clinical and research focus is on cardio-oncology, a new evolving discipline to help manage cancer patients with pre-existing cardiovascular disease or who develop cardiac issues during their cancer treatment. I work collaboratively with the oncology team to maximize the use of lifesaving chemotherapy and minimize any delays in cancer treatment.

Due to of the major advancements in cancer treatments there is a tremendous growth in the number of cancer survivors who have a unique set of challenging medical issues that must be addressed. It is estimated that by year 2020, there will be roughly 18 million cancer survivors in the United States, one of the largest growing population of individuals who will be accessing the health care system.  Heart disease in cancer survivors is one of the leading causes of death behind recurrent cancer, and thus cardio-oncology programs are well suited to help cancer survivors assess cardiac risk factors, prevent future cardiac problems and ultimately improve overall quality of life. Our cardio-oncology program provides comprehensive care focused on prevention and maintenance of cardiovascular disease with incorporation of healthy lifestyle factors. Our collaborative team works closely with cancer survivorship programs and cancer rehabilitation specialists to return survivors to a high quality of life.

Literature Cited – Up to 5 (Optional):

  1. Geisberg CA, Abdallah WM, da Silava M, Silverstein C, Smith HM, Abramson V, Mayer I,Means-Powell J, Freehardt D, White B, Lenihan D, Sawyer D; Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort. Journal of Cardiac Failure 2013;19(1):10-5
  2. Lenneman AJ, Wang L, Wigger M, Frangoul H, Harrell FE, Silverstein C, Sawyer DB, Lenneman CG, Heart Transplant Survival Outcomes with Adriamycin Dilated Cardiomyopathy, American Journal of Cardiology 2013; 111(4):609-12
  3. Geisberg C, Sawyer D. Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage. Current Hypertension Report, 2010;12(6):404-10
  4. Geisberg C, Lenihan D. Cardiac Side Effects of Anticancer Treatments: New Mechanistic Insights. Herz, 2011;Jun;36(4):306-1
  5. Lenneman CG, Abdallah WM, Smith HM, Abramson V, Mayer IA, Silverstein C, Means-Powell J, Paranjape SY, Lenihan D, Sawyer DB and  Raj SR. Sympathetic nervous system alterations with HER2 antagonism: an early marker of cardiac dysfunction with breast cancer treatment? ECancer. 2014; Jul 8:446.

PubMed Information

Additional Information: